PEPG Logo

PepGen Inc. (PEPG) 

NASDAQ
Market Cap
$235.3M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
14 of 776
Rank in Industry
12 of 433

Largest Insider Buys in Sector

PEPG Stock Price History Chart

PEPG Stock Performance

About PepGen Inc.

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the …

Insider Activity of PepGen Inc.

Over the last 12 months, insiders at PepGen Inc. have bought $27.22M and sold $1.04M worth of PepGen Inc. stock.

On average, over the past 5 years, insiders at PepGen Inc. have bought $21.66M and sold $827,860 worth of stock each year.

Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $680.32M. McArthur James G (President and CEO) — $7,056.

The last purchase of 2,557,593 shares for transaction amount of $27.21M was made by RA CAPITAL MANAGEMENT, L.P. () on 2024‑02‑09.

List of Insider Buy and Sell Transactions, PepGen Inc.

2024-07-25SaleChief Medical Officer
7,571
0.0234%
$18.06$136,741-49.64%
2024-07-24SaleChief Medical Officer
201
0.0006%
$18.01$3,6190.00%
2024-07-18SaleChief Medical Officer
12,625
0.0427%
$18.20$229,804-45.13%
2024-07-16SaleChief Medical Officer
5,901
0.0194%
$18.00$106,247-49.33%
2024-07-12SaleChief Medical Officer
3,288
0.0108%
$18.04$59,3310.00%
2024-07-02SaleChief Medical Officer
37
0.0001%
$18.07$6690.00%
2024-07-01SaleChief Medical Officer
875
0.0029%
$18.01$15,7600.00%
2024-06-24SaleChief Medical Officer
9,260
0.0291%
$18.19$168,427-48.60%
2024-06-12SaleChief Medical Officer
1,086
0.0034%
$18.06$19,615-47.66%
2024-06-11SaleChief Medical Officer
500
0.0016%
$18.04$9,022-48.19%
2024-06-06SaleSVP, Clinical Development
1,411
0.0045%
$18.00$25,398-46.08%
2024-06-05SaleSVP, Clinical Development
7,245
0.0223%
$18.09$131,062-48.43%
2024-05-17SaleSVP, Chem. Mfg & Controls
10,000
0.0306%
$13.41$134,100-27.33%
2024-02-09Purchase
2.56M
10.4935%
$10.64$27.21M-9.75%
2023-11-30PurchasePresident and CEO
1,694
0.006%
$4.17$7,056+136.80%
2023-06-08SalePresident and CEO
2,381
0.0098%
$16.04$38,188-54.91%
2023-06-07SalePresident and CEO
8,419
0.0366%
$16.23$136,618-52.77%
2023-06-06SalePresident and CEO
18,150
0.076%
$16.18$293,660-54.30%
2023-06-05SalePresident and CEO
500
0.0022%
$16.06$8,028-52.58%
2023-06-02SalePresident and CEO
1,800
0.0075%
$16.04$28,863-54.46%

Insider Historical Profitability

2.42%
RA CAPITAL MANAGEMENT, L.P.
9179273
28.1662%
$7.2210
McArthur James GPresident and CEO
1694
0.0052%
$7.2215
Oxford Science Enterprises plc10 percent owner
4755388
14.5917%
$7.2210
Shah Rajeev M.
1302600
3.997%
$7.2210+7.35%
Deerfield Private Design Fund V, L.P.
476813
1.4631%
$7.2210+7.35%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
RA Capital Management, L.P.$157.14M32.9810.69M+31.45%+$37.6M0.16
Suvretta Capital Management, LLC$22.36M4.691.52M+212.56%+$15.2M0.94
Frazier Life Sciences Management L P$22.09M4.641.5MNew+$22.09M1
Viking Global Investors$21.79M4.571.48M0%+$00.01
Perceptive Advisors$20.73M4.351.41MNew+$20.73M0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.